232 related articles for article (PubMed ID: 23524581)
1. BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.
Sung M; Giannakakou P
Oncogene; 2014 Mar; 33(11):1418-28. PubMed ID: 23524581
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic strategies to overcome taxane resistance in cancer.
Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
[TBL] [Abstract][Full Text] [Related]
3. Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers.
Wang R; Wang H; Wang Z
J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287508
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
5. +TIP EB1 downregulates paclitaxel‑induced proliferation inhibition and apoptosis in breast cancer cells through inhibition of paclitaxel binding on microtubules.
Thomas GE; Sreeja JS; Gireesh KK; Gupta H; Manna TK
Int J Oncol; 2015 Jan; 46(1):133-46. PubMed ID: 25310526
[TBL] [Abstract][Full Text] [Related]
6. A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells.
Rong D; Wang C; Zhang X; Wei Y; Zhang M; Liu D; Farhan H; Momen Ali SA; Liu Y; Taouil A; Guo W; Wang Y; Ojima I; Yang S; Wang H
Cancer Lett; 2020 Oct; 491():36-49. PubMed ID: 32730778
[TBL] [Abstract][Full Text] [Related]
7. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
8. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.
Sampath D; Discafani CM; Loganzo F; Beyer C; Liu H; Tan X; Musto S; Annable T; Gallagher P; Rios C; Greenberger LM
Mol Cancer Ther; 2003 Sep; 2(9):873-84. PubMed ID: 14555706
[TBL] [Abstract][Full Text] [Related]
9. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.
Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM
Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298
[TBL] [Abstract][Full Text] [Related]
10. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cai P; Lu P; Sharom FJ; Fang WS
Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1.
Dong XL; Xu PF; Miao C; Fu ZY; Li QP; Tang PY; Wang T
Biomed Pharmacother; 2012 Feb; 66(1):70-5. PubMed ID: 22264882
[TBL] [Abstract][Full Text] [Related]
12. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
Haynes BM; Cunningham K; Shekhar MPV
BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
[TBL] [Abstract][Full Text] [Related]
13. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
[TBL] [Abstract][Full Text] [Related]
14. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.
Darshan MS; Loftus MS; Thadani-Mulero M; Levy BP; Escuin D; Zhou XK; Gjyrezi A; Chanel-Vos C; Shen R; Tagawa ST; Bander NH; Nanus DM; Giannakakou P
Cancer Res; 2011 Sep; 71(18):6019-29. PubMed ID: 21799031
[TBL] [Abstract][Full Text] [Related]
15. Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer.
Galletti G; Zhang C; Gjyrezi A; Cleveland K; Zhang J; Powell S; Thakkar PV; Betel D; Shah MA; Giannakakou P
Clin Cancer Res; 2020 Jul; 26(14):3771-3783. PubMed ID: 32321717
[TBL] [Abstract][Full Text] [Related]
16. Multi-CpG linear regression models to accurately predict paclitaxel and docetaxel activity in cancer cell lines.
Bacolod MD; Fisher PB; Barany F
Adv Cancer Res; 2023; 158():233-292. PubMed ID: 36990534
[TBL] [Abstract][Full Text] [Related]
17. Glucose-regulated protein 94 modulates the therapeutic efficacy to taxane in cervical cancer cells.
Tai CJ; Wang JW; Su HY; Tai CJ; Wang CK; Wu CT; Lien YC; Chang YJ
Tumour Biol; 2014 Jan; 35(1):403-10. PubMed ID: 23929391
[TBL] [Abstract][Full Text] [Related]
18. FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression.
Heuer TS; Ventura R; Mordec K; Lai J; Fridlib M; Buckley D; Kemble G
EBioMedicine; 2017 Feb; 16():51-62. PubMed ID: 28159572
[TBL] [Abstract][Full Text] [Related]
19. Dissecting paclitaxel-microtubule association: quantitative assessment of the 2'-OH group.
Sharma S; Lagisetti C; Poliks B; Coates RM; Kingston DG; Bane S
Biochemistry; 2013 Apr; 52(13):2328-36. PubMed ID: 23473345
[TBL] [Abstract][Full Text] [Related]
20. Mechanical aspects of microtubule bundling in taxane-treated circulating tumor cells.
Kim M; Rejniak KA
Biophys J; 2014 Sep; 107(5):1236-1246. PubMed ID: 25185559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
